Q2 2026 · 13F-HR
Sanofi (SNY, SNYNF)holdings as filed
Filed 2026-07-28 · accession 0001193125-26-318812
$534.0M
Reported value
10
Positions
2026-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G59665102 | MGTX | MeiraGTx Holdings plc | $164.8M | 30.9% | 12,197,737 | Common | SOLE |
| 45720N103 | INBX | Inhibrx Biosciences, Inc. | $109.7M | 20.5% | 1,157,926 | Common | SOLE |
| 670002401 | NVAX | Novavax | $64.8M | 12.1% | 6,880,481 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio | $55.5M | 10.4% | 821,917 | Common | SOLE |
| 67613T104 | ODTX | Odyssey Therapeutics Inc. | $37.3M | 6.98% | 1,991,918 | Common | SOLE |
| 00860C102 | AGMB | Agomab Therapeutics NV | $36.1M | 6.76% | 2,783,096 | Common | SOLE |
| 56565P103 | MPLT | MapLight Therapeutics Inc. | $32.7M | 6.12% | 912,041 | Common | SOLE |
| 337185102 | TRAX | First Tracks Biotherapeutics Inc. | $16.5M | 3.10% | 821,917 | Common | SOLE |
| 45254E107 | IMRX | Immuneering Corp | $13.5M | 2.53% | 2,708,559 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio Inc. | $3.1M | 0.58% | 244,083 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.